Related Experiment Video
Updated: Jun 16, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
[Etravirine in highly treatment-experienced patients]
Daniel Podzamczer Palter1, Elena Ferrer Corbera, Juan Manuel Tiraboschi
1Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, España. dpodzamczer@bellvitgehospital.cat
Enfermedades Infecciosas Y Microbiologia Clinica
|February 2, 2010
Summary
Etravirine (ETR) effectively treats patients with HIV who have prior treatment failures. This non-nucleoside reverse transcriptase inhibitor (NNRTI) shows superior virological and immunological responses with good tolerability.
Area of Science:
- Antiviral Therapy
- HIV/AIDS Research
- Pharmacology
Background:
- Etravirine (ETR) is an effective non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with multi-drug resistant HIV.
- Previous evidence from DUET studies demonstrated ETR's efficacy and safety in heavily pre-treated patients.
Purpose of the Study:
- To summarize the efficacy and tolerability of Etravirine (ETR) in managing HIV infection.
- To highlight ETR's role in current combination antiretroviral therapy regimens.
Main Methods:
- Review of data from DUET I and DUET II multicenter, randomized, double-blind clinical trials.
- Analysis of results from the TRIO study evaluating ETR in combination therapy.
Main Results:
- DUET studies showed superior virological and immunological response with ETR compared to placebo, reducing AIDS progression.
- The most common adverse event was mild to moderate rash (2% discontinuation); no significant GI, liver, or lipid toxicity.
- The TRIO study demonstrated excellent virological (<50 copies/mL) and immunological (CD4 +108) response at 48 weeks with an ETR-containing regimen.
Conclusions:
- Etravirine (ETR) is effective and well-tolerated for HIV patients with prior treatment failures.
- ETR's high genetic barrier and long half-life enable its use in sequential NNRTIs and once-daily dosing regimens.
Related Concept Videos
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:10Retrovirus Life Cycles
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:18Trichomoniasis
Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.